Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) - Related Studies

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate016)

This study is currently recruiting participants.

Verified May 2013 by Bristol-Myers Squibb

Study NCT01472081 Information provided by Bristol-Myers Squibb

First Received on October 26, 2011. Last Updated on May 14, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Renal Cell Carcinoma

Additional conditions recognized in this trial

Carcinoma
Carcinoma, Renal Cell

More general conditions related to this trial

Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

Interventions listed in this trial

Nivolumab
Pazopanib
Sunitinib
Ipilimumab

More general drug interventions related to this trial

Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

Sponsors listed in this trial

Bristol-Myers Squibb
Ono Pharmaceutical Company, Ltd.